L-carnitine Supplementation For The Management Of Fatigue In Patients With Hypothyroidism On Levothyroxine Treatment: A Randomized, Double-blind, Placebo-controlled Trial
Notes for this study:
|| (µIU/mL) Mean and SD. Placebo: before 0.98 ± 1.10, after 1.11 ± 1.28. Carnitine: before 0.83 ± 1.22, after 0.92 ± 1.02.
|Number of Subjects
||18-29, 30-44, 45-64, 65+
In 12-week, randomized, double-blind, placebo-controlled trial, 60 participants with primary hypothyroidism who were taking levothyroxine took 1 g of l-carnitine daily or placebo.
The primary outcome was fatigue, and there was a statistically significantly greater reduction in mental fatigue with carnitine, but a nonsignificant reduction with physical fatigue and fatigue severity index. When considered as a percentage who saw improvement, the carnitine group saw statistically significant improvements for all. Younger (less than 50) participants saw greater effects.
There wasn't a statistically significant difference for body composition, fasting glucose, liver enzymes, HbA1c, lipid panel, or thyroid hormones.
There weren't notable differences in adverse events.